Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers
NCT ID: NCT00624130
Last Updated: 2014-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
453 participants
INTERVENTIONAL
2004-03-31
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Yasmin 20
Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
Arm 2
Mercilon
Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Yasmin 20
Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
Mercilon
Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Smokers 18-30
Exclusion Criteria
18 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Horn, , Austria
Leibnitz, Styria, , Austria
Mödling, , Austria
Sankt Pölten, , Austria
Vienna, , Austria
Wörgl, , Austria
Pärnu, , Estonia
Talinn, , Estonia
Tartu, , Estonia
Helsinki, , Finland
Helsinki, , Finland
Tampere, , Finland
Turku, , Finland
Kaunas, , Lithuania
Kaunas, , Lithuania
Vilnius, , Lithuania
Vilnius, , Lithuania
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Anttila L, Neunteufel W, Petraglia F, Marr J, Kunz M. Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 mug compared with a 21/7 regimen of desogestrel 150 mug/ethinylestradiol 20 mug: a pooled analysis. Clin Drug Investig. 2011;31(8):519-525. doi: 10.2165/11590260-000000000-00000.
Anttila L, Bachmann G, Hernadi L, Kunz M, Marr J, Klipping C. Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 mug/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. Eur J Obstet Gynecol Reprod Biol. 2011 Apr;155(2):180-2. doi: 10.1016/j.ejogrb.2010.12.037. Epub 2011 Feb 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
308020
Identifier Type: -
Identifier Source: secondary_id
91352
Identifier Type: -
Identifier Source: org_study_id